Among the Covid-19 treatments given to President Trump last weekend was a cocktail of antibodies against the coronavirus, from
announced that it, too, has a cocktail of two antibodies that helped Covid patients avoid the hospital in a Phase 2 clinical trial.
Lilly (ticker: LLY) has asked federal regulators for an emergency authorization to distribute a treatment that uses a single antibody—a request that it will later make for the cocktail and which is also being sought by Regeneron (REGN).
Lilly stock was up 3% Wednesday morning, to $148, after the drug company released some results from its antibody cocktail trial. Regeneron shares traded in line with the overall market, rising 1% to $589. Shares of
(VIR) on Tuesday jumped when